Welcome to our dedicated page for Haleon plc SEC filings (Ticker: HLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Haleon plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Haleon plc's regulatory disclosures and financial reporting.
Haleon plc announced the purchase of 5,150,000 ordinary shares under the second tranche of its share buyback programme. The Company intends to hold the purchased shares as treasury shares. After settlement, registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 28,187,545 are held as treasury shares, leaving 8,924,166,103 ordinary shares with voting rights. A full breakdown of individual trades is available via the provided London Stock Exchange link and on the Company website.
Haleon plc reported small share purchases by two senior insiders through dividend reinvestment. On 18 September 2025, Chief Marketing Officer Tamara Rogers acquired 5 Ordinary Shares of £0.01 each at a price of £3.441 per share on the London Stock Exchange.
On the same date, Independent Non-Executive Director Alan Stewart acquired 214 Ordinary Shares at a price of £3.424442 per share, also via dividend reinvestment on the London Stock Exchange. These transactions were disclosed as required for persons discharging managerial responsibilities.
Haleon plc announced the purchase of 4,150,000 ordinary shares of £0.01 each on 19 September 2025 under the second tranche of its share buyback programme announced 31 July 2025. The shares were purchased on the London Stock Exchange and CBOE (UK)/CXE across the session; a full breakdown of individual trades is provided via the Company link. The Company intends to hold the purchased shares as treasury shares. After settlement, registered share capital is 8,952,353,648 ordinary shares, of which 23,037,545 are treasury shares, leaving 8,929,316,103 voting shares.
Haleon plc reports it purchased 4,314,000 ordinary shares of £0.01 each under the second tranche of its buyback programme announced 31 July 2025. The company intends to hold the purchased shares as treasury shares. After settlement the company's registered share capital is 8,952,353,648 ordinary shares, of which 18,887,545 are treasury shares, leaving 8,933,466,103 ordinary shares with voting rights. Shareholders may use the voting-rights figure to determine notification obligations under the FCA Disclosure Guidance and Transparency Rules. A full breakdown of individual trades is available via the provided RNS link and on the company website.
Haleon plc completed a tranche of its share buyback programme, acquiring 5,214,540 ordinary shares (â£0.01 each) on 17 September 2025. The company intends to hold the purchased shares as treasury shares. After settlement, registered share capital is 8,952,353,648 ordinary shares, of which 14,573,545 are held in treasury, leaving 8,937,780,103 ordinary shares with voting rights. A full breakdown of individual trades is available via the provided RNS link and on the company's investor website.
Haleon plc announced the purchase of 5,357,044 ordinary shares of £0.01 each under the second tranche of its buyback programme. The company will hold the purchased shares as treasury shares. After settlement, registered share capital is 8,952,353,648 ordinary shares, of which 9,359,005 are held in treasury, leaving 8,942,994,643 ordinary shares with voting rights. A full breakdown of individual trades is available via the provided link and on the company's investor website. The announcement notes this does not constitute an offer for securities.
Haleon plc purchased 1,500,000 ordinary shares under the second tranche of its buyback programme announced 31 July 2025. The shares were bought on 15 September 2025 on the London Stock Exchange/CBOE (UK)/CXE and the company intends to hold the purchased shares as treasury shares.
After settlement the company's registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 4,001,961 are held as treasury shares, leaving 8,948,351,687 ordinary shares with voting rights. The announcement points investors to a full trade breakdown at the provided link and to Haleon's investor website for details.
Haleon plc announced on 15 September 2025 that it purchased 997,991 ordinary shares of each under the second tranche of its share buyback programme announced 31 July 2025. Of the purchased shares, 23,788 will be cancelled and 974,203 will be held as treasury shares. After settlement the company's registered share capital is 8,952,353,648 ordinary shares of each, with 2,501,961 held as treasury shares and 8,949,851,687 shares with voting rights.
The announcement notes a full trade breakdown is available via the provided RNS link and on the company's investor website.
Haleon plc reports the purchase and cancellation of 172,878 ordinary shares of £0.01 each under the second tranche of its share buyback programme announced 31 July 2025. Following settlement, registered share capital is 8,952,651,173 ordinary shares, of which 1,580,205 are held as treasury shares, leaving 8,951,070,968 ordinary shares with voting rights. A full breakdown of individual trades is available via the provided RNS link and on the company website.
Haleon plc (LSE/NYSE: HLN) disclosed a notification under the UK Market Abuse Regulation for a transaction by a Person Discharging Managerial Responsibilities (PDMR). The Company received the notice on 10 September 2025 and reported an executed trade of 34 matching shares at a price of £3.6182 per share. The filing is a routine regulatory disclosure of insider dealing activity and includes the Company’s principal office address in Weybridge, Surrey.
The document also lists Haleon’s consumer brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren, and directs readers to www.haleon.com for more information. The filing contains transaction detail limited to volume and price; other typical fields are present in template form but not populated with additional substantive data.